Bench Scientist

Artech is the 10th Largest IT Staffing Company in the US, according to Staffing Industry Analysts' 2012 annual report. Artech provides technical expertise to fill gaps in clients' immediate skill-sets availability, deliver emerging technology skill-sets, refresh existing skill base, allow for flexibility in project planning and execution phases, and provide budgeting/financial flexibility by offering contingent labor as a variable cost.

The qualified candidate will join the Bioassay and Impurities Testing group, which is part of the Analytical R&D organization located in STL, MO to enable the development of biological therapeutics at Pharmaceutical. 

• The position will be part of a highly matrixed team responsible for developing analytical methodologies (Cell Based, ELISA, DNA) and strategies needed to progress biotherapeutic products through the pipeline. Responsibilities include specific method development and method testing via ELISA and Cell-Based assays, as well as host cell impurity testing. The deliverables of the project are to complete method development, implementation and transfer to partners as needed. 

• The scientist filling this position will work within a highly matrixed team setting on variety of modalities including vaccines, viral constructs, therapeutic proteins and monoclonal antibodies. The contractor will work in a cGMP testing environment doing method development, qualification, and testing. 

• Experience with ELISA, Cell-Based assays, Luminex (or Bioplex), cell culture, DNA (qPCR) method development, and method qualification. 
  
• Must have ELISA based experience in biotherapeutics. 
  
• Cell based is preferable.
  
• Looking for intermediate candidate with at least 3 years of experience 
  

Skills:

• ELISA experience is required
  

Sneha Shrivastava

Technical Recruiter (Clinical/Scientific)

Artech Information Systems LLC

360 Mt. Kemble Avenue, Suite 2000 | Morristown, NJ 07960 

Office: 973.967.3348 | Fax: 973.998.2599

Connect with us on - LinkedIn | Facebook | Twitter